Thalidomide and its analogs for hemoglobinopathies: Two birds with one stone?

Expert Review of Hematology

Volumn 5, Issue 1, 2012, Pages 9-11

  Kutlar, Abdullah ^a   Meiler, Steffen ^a   Swerdlow, Paul ^b   Knight, Robert ^c  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c CELGENE CORPORATION   (United States)

Author keywords

thalassemias; pomalidomide; sickle cell disease; thalidomide

Indexed keywords

CD34 ANTIGEN; CELL ADHESION MOLECULE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HEMOGLOBIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 5; L SELECTIN; LENALIDOMIDE; MESSENGER RNA; POMALIDOMIDE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; BUTYRIC ACID; GAMMA INTERFERON; GLOBIN MESSENGER RNA; HEMOGLOBIN F; HISTONE H4; HYDROXYUREA; INTERLEUKIN 2; LYMPHOTOXIN; MITOGEN ACTIVATED PROTEIN KINASE P38; THALIDOMIDE DERIVATIVE; VASCULAR CELL ADHESION MOLECULE 1;

ACETYLATION; AMYLOIDOSIS; ANGIOGENESIS; BEHCET DISEASE; CANCER GROWTH; CELL VIABILITY; CHROMOSOME 5Q; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; CROHN DISEASE; CYTOTOXICITY; DISCOID LUPUS ERYTHEMATOSUS; DRUG EFFICACY; EDITORIAL; GERMANY; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBINOPATHY; HUMAN; IMMUNE RESPONSE; INFLAMMATION; KIDNEY CANCER; LYMPHOMA; METASTASIS; MONOCYTE; MORNING SICKNESS; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PREGNANCY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; SICKLE CELL ANEMIA; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL; TH2 CELL; 5Q- SYNDROME; ALLOIMMUNIZATION; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; AUSTRALIA; BETA THALASSEMIA; BIRTH DEFECT; CD34 SELECTION; CELL CULTURE; CONGESTIVE HEART FAILURE; DISEASE SEVERITY; DRUG APPROVAL; DRUG CYTOTOXICITY; DRUG POTENCY; ERYTHEMA NODOSUM LEPROSUM; ERYTHROPOIESIS; EUROPE; HEMOGLOBIN SYNTHESIS; HISTONE ACETYLATION; IN VITRO STUDY; MEDLINE; MULTIPLE MYELOMA; PHOCOMELIA; PRACTICE GUIDELINE; TH1 TH2 BALANCE; TRANSGENIC MOUSE;

ANIMALS; HEMOGLOBINOPATHIES; HUMANS; MICE; THALIDOMIDE;

EID: 84856262418     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.11.77     Document Type: Editorial

References (11)

1. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat. Rev. Cancer 4(4), 314-322 (2004). (Pubitemid 38525287)
2. Kumar S, Witzig TE, Rajkumar SV. Thalidomide as an anti-cancer agent. J. Cell Mol. Med. 6(2), 160-174 (2002). (Pubitemid 44133967)
3. Weeber M, Vos R, Klein H, De Jong-Van Den Berg LT, Aronson AR, Molema G. Generating hypotheses by discovering implicit associations in the literature: a case report of a search for new potential therapeutic uses for thalidomide. J. Am. Med. Inform. Assoc. 10(3), 252-259 (2003). (Pubitemid 36554786)
4. Hebbel RP, Osarogiagbon R, Kaul D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation 11(2), 129-151 (2004). (Pubitemid 39619075)
5. Walmet PS, Eckman JR, Wick TM. Inflammatory mediators promote strong sickle cell adherence to endothelium under venular flow conditions. Am. J. Hematol. 73(4), 215-224 (2003). (Pubitemid 36898876)
6. Moutouh-de Parseval LA, Verhelle D, Glezer E et al. Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells. J. Clin. Invest. 118(1), 248-258 (2008).
7. Aerbajinai W, Zhu J, Gao Z, Chin K, Rodgers GP. Thalidomide induces g-globin gene expression through increased reactive oxygen species-mediated p38 MAPK signaling and histone H4 acetylation in adult erythropoiesis. Blood 110(8), 2864-2871 (2007). (Pubitemid 350006939)
8. Meiler SE, Wade M, Kutlar F et al. Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice. Blood 118(4), 1109-1112 (2011).
9. Aguilar-Lopez LB, Delgado-Lamas JL, Rubio-Jurado B, Perea FJ, Ibarra B. Thalidomide therapy in a patient with thalassemia major. Blood Cells Mol. Dis. 41(1), 136-137 (2008).
10. Masera N, Tavecchia L, Capra M et al. Optimal response to thalidomide in a patient with thalassaemia major resistant to conventional therapy. Blood Transfus. 8(1), 63-65 (2010).
11. Begna KH, Mesa RA, Pardanani A et al. A Phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia 25(2), 301-304 (2011).